LLY - Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor
- Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement.
- Stemirna Therapeutics raised nearly $200 million to finance clinical trials and production of its messenger RNA COVID-19 vaccine candidate.
- Suzhou Innovent Biologics acquired China rights to co-develop and commercialize taletrectinib, an AnHeart oncology treatment, in a $189 million pact.
- LianBioacquired China rights to a long-term treatment for chronic rhinosinusitis fromLyra Therapeutics in an agreement worth up to $147 million.
For further details see:
Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor